All In Biotech

Drug Trial Radar · NCT04936035

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension

Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 394 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

394

Actual

Start

Jul 7, 2021

Primary completion

Apr 4, 2023

Study completion Dec 5, 2024

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Jun 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.

Conditions

  • Hypertension

Interventions

  • PlaceboDrug

    Placebo administered by SC injection

  • ALN-AGT01Drug

    ALN-AGT01 administered by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPMTime frame: Baseline and Month 3

Locations

75 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Birmingham, Alabama

  • Clinical Trial Site

    Tempe, Arizona

  • Clinical Trial Site

    Tempe, Arizona

  • Clinical Trial Site

    Beverly Hills, California

  • Clinical Trial Site

    La Mesa, California

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    San Diego, California

  • Clinical Trial Site

    South Gate, California

  • Clinical Trial Site

    Vista, California

  • Clinical Trial Site

    Washington D.C., District of Columbia

  • Clinical Trial Site

    Clearwater, Florida

  • Clinical Trial Site

    Coral Gables, Florida

  • Clinical Trial Site

    Fleming Island, Florida

  • Clinical Trial Site

    Hollywood, Florida

  • Clinical Trial Site

    Hollywood, Florida

  • Clinical Trial Site

    Inverness, Florida

  • Clinical Trial Site

    Jacksonville, Florida

  • Clinical Trial Site

    Jacksonville, Florida

  • Clinical Trial Site

    Jacksonville, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Naples, Florida

  • Clinical Trial Site

    Orlando, Florida

  • Clinical Trial Site

    Acworth, Georgia

  • Clinical Trial Site

    Columbus, Georgia

  • Clinical Trial Site

    Fayetteville, Georgia

  • Clinical Trial Site

    Macon, Georgia

  • Clinical Trial Site

    Champaign, Illinois

  • Clinical Trial Site

    Valparaiso, Indiana

  • Clinical Trial Site

    West Des Moines, Iowa

  • Clinical Trial Site

    Lake Charles, Louisiana

  • Clinical Trial Site

    New Orleans, Louisiana

  • Clinical Trial Site

    Prairieville, Louisiana

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Jackson, Mississippi

  • Clinical Trial Site

    Jefferson City, Missouri

  • Clinical Trial Site

    Las Vegas, Nevada

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    The Bronx, New York

  • Clinical Trial Site

    Greensboro, North Carolina

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.